Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Price Target from Analysts

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have been given an average recommendation of “Buy” by the six research firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $23.67.

A number of equities analysts have commented on the stock. BMO Capital Markets dropped their target price on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a report on Thursday, November 14th.

Acrivon Therapeutics Stock Down 4.2 %

ACRV stock opened at $5.45 on Monday. The firm has a market cap of $169.71 million, a price-to-earnings ratio of -2.02 and a beta of 0.77. Acrivon Therapeutics has a twelve month low of $3.19 and a twelve month high of $11.90. The business’s fifty day simple moving average is $6.41 and its two-hundred day simple moving average is $7.40.

Institutional Trading of Acrivon Therapeutics

A number of hedge funds have recently bought and sold shares of ACRV. Perceptive Advisors LLC lifted its position in shares of Acrivon Therapeutics by 78.2% during the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock valued at $31,093,000 after buying an additional 2,353,000 shares during the last quarter. Barclays PLC boosted its stake in Acrivon Therapeutics by 51.2% in the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after acquiring an additional 11,273 shares in the last quarter. State Street Corp grew its holdings in Acrivon Therapeutics by 26.4% in the third quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after purchasing an additional 47,233 shares during the last quarter. Marshall Wace LLP increased its position in shares of Acrivon Therapeutics by 58.8% during the second quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock worth $5,503,000 after purchasing an additional 351,397 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Acrivon Therapeutics during the 2nd quarter valued at $61,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.